Medscape women's health最新文献

筛选
英文 中文
Hearing Loss: Does Gender Play a Role? 听力损失:性别起作用吗?
Medscape women's health Pub Date : 1997-10-01
Murphy, Gates
{"title":"Hearing Loss: Does Gender Play a Role?","authors":"Murphy,&nbsp;Gates","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An estimated 8 million women in the US have difficulty hearing, and 2 million of those are able to hear, at best, only shouted words. Women of all ages have better hearing than men at frequencies above 2000Hz. The better pure-tone audiometry thresholds of women at high frequencies is paradoxically accompanied by a \"gender reversal\" in which women, as they age, have a poorer capacity to hear at low frequencies--specifically those below the 1000- to 2000-Hz range--than do men. Thus, the pattern of hearing loss with aging may differ between women and men. The hypothesized role of ovarian hormones and cardiovascular disease in hearing loss is reviewed, and such interventions as cochlear implants to correct hearing loss in women are highlighted. Research into organ of Corti hair-cell regeneration is ongoing and may offer recovery of hearing in the next century.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 10","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"1997-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From GnRH to SSRIs and Beyond: Weighing the Options for Drug Therapy in Premenstrual Syndrome. 从GnRH到SSRIs及其他:权衡经前期综合征药物治疗的选择。
Medscape women's health Pub Date : 1997-10-01
Mortola
{"title":"From GnRH to SSRIs and Beyond: Weighing the Options for Drug Therapy in Premenstrual Syndrome.","authors":"Mortola","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pharmacologic intervention is now the most effective therapy available for treating premenstrual syndrome (PMS). Although there are still no Food and Drug Administration-approved medications for this indication, several well-designed studies have been conducted, the results of which may guide the clinician's treatment of women with this disorder. Consequently, less-proven nonpharmacologic modalities, such as dietary modification, exercise regimens, and psychotherapy, are more readily supplanted by the use of medication. Three classes of agents have been shown to have varying degrees of effectiveness in relieving PMS symptoms and are increasingly being used to treat the disorder: gonadotropin-releasing hormone (GnRH) agonists, benzodiazepines, and selective serotonin reuptake inhibitors (SSRIs). While the GnRH agonists like leuprolide acetate, nafarelin acetate, or goserelin acetate have been shown to be highly effective in select cases, their side effects relegate them to use in patients who are unresponsive to other agents. More recently, the benefits of alprazolam (a benzodiazepine) and the SSRIs (especially fluoxetine) have been definitively established. In addition to these medications used to treat premenstrual syndrome in general, other drugs that are used to treat specific aspects of the disorder include danazol for headaches and spironolactone for fluid retention.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 10","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"1997-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosing and Treating Breast Cancer in the Pregnant Woman. 孕妇乳腺癌的诊断和治疗。
Medscape women's health Pub Date : 1997-10-01
DiFronzo, O'Connell
{"title":"Diagnosing and Treating Breast Cancer in the Pregnant Woman.","authors":"DiFronzo,&nbsp;O'Connell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Because breast cancer is an uncommon occurrence during pregnancy, symptoms and signs of the disease may be overlooked, resulting in delays in treatment and potentially compromising survival. In many cases, the physician may mistake signs of disease for the normal physiologic changes of pregnancy. For this reason, it is imperative that physicians perform careful clinical breast examinations in all pregnant patients--particularly early in gestation, before the breasts become difficult to examine. Upon finding any suspicious breast mass, an open biopsy without delay is indicated. Once a diagnosis of breast cancer is confirmed, a modified radical mastectomy is the treatment of choice in a pregnant woman because of the hazards of adjuvant therapy to the fetus. The administration of adjuvant therapy, such as radiation therapy or chemotherapy, may pose a risk to the fetus and requires careful consideration by the physician and patient. In some cases, especially when disease presents early in gestation, an interruption of the pregnancy may be warranted. Importantly, stage for stage, breast cancer during pregnancy has a similar prognosis to that of breast cancer in young, nonpregnant women; pregnancy itself does not appear to have an adverse effect on the disease process. In addition, with careful counseling, pregnancy subsequent to breast cancer is possible for some women with good prognoses.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 10","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"1997-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recognizing and Managing the Oral Clues That Point to Sjögren's Syndrome. 识别和管理指向Sjögren综合征的口头线索。
Medscape women's health Pub Date : 1997-09-01
Aguirre
{"title":"Recognizing and Managing the Oral Clues That Point to Sjögren's Syndrome.","authors":"Aguirre","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sjögren's syndrome (SS), a chronic autoimmune exocrinopathy, occurs mainly after age 40. Most SS patients--80% to 90%--are women. SS is characterized by dry eyes and mouth due to lacrimal and salivary gland lymphocytic infiltration. It may be primary or secondary in association with a connective tissue disease, usually rheumatoid arthritis. Lymphoproliferation may produce extraglandular manifestations in pulmonary, cardiac, genitourinary, vascular, and/or nervous systems. The risk of lymphoma is increased 40-fold among SS patients. Dry mouth, or xerostomia, hinders eating, speaking, and swallowing. A thorough patient history, serum analysis, and salivary function tests are essential to determine the genesis of the xerostomia. Insufficient salivary protection can cause rampant dental destruction and soft-tissue mycosis in the mouth. A biopsy of the minor salivary gland from the lower lip is used to detect hallmark inflammatory changes that confirm the diagnosis of SS. Therapy is symptomatic. Regardless of the cause of xerostomia, therapy has 3 fundamental aspects: preventive dental care, dietary counseling (reduction of sugar intake to avoid caries), and moisture replacement (including artificial salivas, frequent sips of water, and room humidifiers). Women taking xerostomic medications may need to lower the dose or substitute them with less xerogenic drugs if possible. Salivation can be stimulated by chewing gum, mints, or paraffin. Cracked lips are treated with petroleum. Dental flossing, supplemental fluoride, and dental appointments every 3 to 4 months are essential to control caries. Pilocarpine, a parasympathomimetic drug that increases salivation, has been found to reduce the severity of xerostomia from radiotherapy; multicenter trials in SS patients are ongoing.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 9","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"1997-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying and Treating Depression in Women With Cancer: A Primary Care Approach. 鉴别和治疗女性癌症患者的抑郁症:一种初级保健方法。
Medscape women's health Pub Date : 1997-09-01
Strouse
{"title":"Identifying and Treating Depression in Women With Cancer: A Primary Care Approach.","authors":"Strouse","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In general, depressive disorders in the US are more common in women than in men. In women with cancer, approximately 20% to 25% experience clinically significant depression and/or anxiety at some point during the course of medical treatment. This report profiles the differential diagnosis of depressive disorders as well as special medical variables, treatment options, and follow-up considerations for women with cancer. A range of psychotherapeutic and somatic treatments are available, with selective serotonin reuptake inhibitor antidepressants being the mainstay of drug therapy. Despite an array of available treatments, depression in patients with cancer remains underdiagnosed and undertreated; it is imperative that these patients be treated for both of their diseases. Depression left untreated in women with cancer may not only cause significant emotional suffering but also slower medical recovery, less adaptive health behaviors, and a negative effect on medical outcome and, ultimately, on survival. Patients who do not respond to conventional treatment approaches should be referred to a consulting psychiatrist for confirmation of diagnosis and consideration of other treatment options.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 9","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"1997-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weighing The Options In Medical Abortion. 权衡药物流产的选择。
Medscape women's health Pub Date : 1997-09-01
Schaff, Eisinger, Stadalius
{"title":"Weighing The Options In Medical Abortion.","authors":"Schaff,&nbsp;Eisinger,&nbsp;Stadalius","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>For women who require interruption of pregnancy, medications that can offer a safe alternative to surgery--for example, methotrexate (though interruption of pregnancy is not an approved indication) and mifepristone (formerly known as RU486 and currently pending approval by the Food and Drug Administration [FDA])--are being examined. As with any new therapy, clinicians who wish to be able to offer this option should become familiar with the medications' safety and efficacy profiles and how they work, which patients are acceptable candidates, how the procedure is performed, how to counsel women seeking information, and how to manage complications. Nonsurgical abortion using either methotrexate or mifepristone in combination with misoprostol can be a safe and effective alternative to surgical abortion if a woman is no more than 7 weeks pregnant, clinical guidelines are followed, and access to surgical abortion is available for complications. Administration of either agent is followed within days by administration of misoprostol, a prostaglandin that induces uterine contraction and expulsion of the uterine contents. Side effects of all 3 agents are generally mild, but complications may include ongoing pregnancy, incomplete abortion, or excessive bleeding.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 9","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"1997-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gynecology Case Challenge - Spotting and Abnormal Cervix in a Young Woman on Oral Contraceptives. 妇科病例挑战-一名口服避孕药的年轻妇女的斑点和异常宫颈。
Medscape women's health Pub Date : 1997-08-01
Hill
{"title":"Gynecology Case Challenge - Spotting and Abnormal Cervix in a Young Woman on Oral Contraceptives.","authors":"Hill","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 22-year-old primiparous woman on oral contraceptives is referred to you for \"spotting after intercourse\" and an \"abnormal-appearing cervix.\" What is your diagnosis and treatment plan?</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 8","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"1997-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous Bladder Neck Stabilization for Stress Urinary Incontinence in Women: The Technique, Risks, Benefits. 经皮膀胱颈部稳定治疗女性压力性尿失禁:技术、风险和益处。
Medscape women's health Pub Date : 1997-08-01
Appell
{"title":"Percutaneous Bladder Neck Stabilization for Stress Urinary Incontinence in Women: The Technique, Risks, Benefits.","authors":"Appell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent reviews have noted failures of transvaginal surgical procedures designed to cure stress urinary incontinence in women. Modifications continue to be applied to improve the transvaginal approach, including anchoring the supporting sutures to the pelvic bones and reducing the transvaginal dissection to prevent further prolapse. This article reports the outcomes of 2 procedures: a bone-anchoring technique with preservation of the endopelvic fascia in transvaginal suspension surgery for incontinence caused by urethral hypermobility, and a modified sling procedure for incontinence caused by intrinsic sphincteric deficiency. Results of the bone-anchor suspension showed an 81.7% cure rate in 71 patients who were followed for at least 3 years. Findings of the in situ sling procedure with bone anchoring showed a 97.5% cure rate in 40 patients who were followed for at least 2 years. The use of this bone-anchoring technique with preservation of the endopelvic fascia and the use of the modified sling technique appear to enhance the success rate without increasing the risk to the patient. As minimally invasive procedures, they also reduce surgical time and length of hospitalization, thus lowering costs.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 8","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"1997-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preterm Birth: The Role of Infection and Inflammation. 早产:感染和炎症的作用。
Medscape women's health Pub Date : 1997-08-01
McGregor, French
{"title":"Preterm Birth: The Role of Infection and Inflammation.","authors":"McGregor,&nbsp;French","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Preterm birth is the leading preventable cause of neonatal morbidity. Evidence shows that common genitourinary infections, which can easily be treated, cause large numbers of babies to be born prematurely. Because of their biologically immature organs, these newborns require intensive neonatal care, which leads to excess hospital costs early in life (approximately $3000/day at the University of Colorado). Long term, these children require follow-up for a range of disabling conditions, such as cerebral palsy, mental retardation, blindness, and/or deafness. Inexpensive screening during pregnancy can detect such common infections as bacterial vaginosis, trichomoniasis, chlamydia, and urinary tract infection; prompt treatment of these infections can effectively reduce admissions for preterm labor evaluation and can lower preterm birth rates. Bacterial vaginosis, in particular, has been consistently associated with a significantly increased risk of preterm births. Selective use of antibiotics in women during preterm labor and premature rupture of membranes significantly reduces both preterm birth rates and the risk of complications--in particular, from group B streptococcus (GBS) infection--in both babies and mothers. Implementation of appropriate screening and treatment of bacterial vaginosis and other prevalent infections can dramatically reduce the excess morbidity and mortality of infants \"born too soon\" because of reproductive tract infection.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 8","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"1997-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating and Managing Postpartum Thyroid Dysfunction. 产后甲状腺功能障碍的评估和处理。
Medscape women's health Pub Date : 1997-07-01
Mestman
{"title":"Evaluating and Managing Postpartum Thyroid Dysfunction.","authors":"Mestman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Postpartum thyroid dysfunction (PTD) occurs in approximately 5% to 10% of all women within 1 year following delivery and is usually due to intrinsic thyroid disease rather than hypothalamic or pituitary lesions. The most common etiology of PTD, which may resemble postpartum depression, is autoimmune thyroid disease (chronic or Hashimoto's thyroiditis). Women with Graves' disease who experience symptom exacerbation in the postpartum period account for a small percentage of cases. Clues to PTD include nonspecific symptoms such as tiredness, fatigue, depression, palpitations, and irritability. On physical examination, tachycardia may be noted. Goiters are detected in the majority of cases. The disease course varies; most patients experience a phase of hypothyroidism that takes 2 to 6 months to resolve, but some develop permanent hypothyroidism within 5 years of the diagnosis.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 7","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"1997-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20660561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信